

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Mometinib for treating disease-related splenomegaly
or symptoms in adults with myelofibrosis**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During consultation, an issue pertaining to equality was presented. One stakeholder commented that age over 65 years old is a prognostic factor for myelofibrosis and so, there is potential for clinical efficacy and cost effectiveness to vary for populations over and under 65 years.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

NICE is committed to avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity. When considering subgroups, the committee pays particular attention to its legal obligations with respect to legislation on human rights, discrimination and equality when considering subgroups. The committee may recommend a technology for subgroups of the population only if there is clear evidence that the characteristics defining the subgroup influence the effectiveness or value for money of the technology..

3. Has any change to the draft scope been agreed to highlight potential equality issues?

Not required.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Ross Dent

Date: 05/06/2023